Cipla Ltd promoters have confirmed that no shares were encumbered directly or indirectly during the financial year 2025-26. The declaration, submitted to stock exchanges and the audit committee, covers the promoters, the promoter group, and Persons Acting in Concert (PAC).

The disclosure was made under Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirms that no shares of Cipla Ltd were pledged by these entities during the specified period.

The declaration was signed by Dr Y K Hamied and Mr M K Hamied on April 1, 2026. The communication was addressed to the BSE Ltd, National Stock Exchange of India Ltd, the Audit Committee of Cipla Ltd, and the Societe De La Bourse De Luxembourg.

Key Details

Cipla is expanding its manufacturing footprint for respiratory and specialty products across three major markets — India, China, and the United States. The development underscores the company's strategic focus on strengthening production capabilities in therapeutically significant segments that cater to both domestic and international demand.

Manufacturing Expansion Across Key Markets

The expansion spans geographies that represent critical nodes in Cipla's global supply chain and commercial strategy. India, as the company's home base, alongside China and the U.S., forms a triangulated manufacturing presence aimed at supporting the respiratory and specialty product portfolios.

Respiratory therapeutics and specialty products are among the more complex segments in pharmaceutical manufacturing, typically requiring advanced formulation capabilities and stringent regulatory compliance across multiple jurisdictions. Cipla's move to grow manufacturing in these areas across three distinct regulatory environments reflects the scale of the initiative.

Strategic Significance

The simultaneous expansion across India, China, and the U.S. positions Cipla to address supply requirements in both emerging and developed markets. Respiratory products, in particular, represent a segment with consistent global demand, making manufacturing scale a key competitive factor. Specialty products, which often involve biologics, complex generics, or niche therapies, similarly benefit from expanded and diversified production infrastructure.